740 related articles for article (PubMed ID: 25894155)
1. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of tandem hemodialysis and immunoadsorption to desensitize kidney transplant candidates.
Rostaing L; Maggioni S; Hecht C; Hermelin M; Faudel E; Kamar N; Sallusto F; Doumerc N; Allal A
Exp Clin Transplant; 2015 Apr; 13 Suppl 1():165-9. PubMed ID: 25894148
[TBL] [Abstract][Full Text] [Related]
3. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
[TBL] [Abstract][Full Text] [Related]
4. Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases.
Rostaing L; Karam B; Congy-Jolivet N; Hage V; Sallusto F; Esposito L; Doumerc N; Debiol B; Guilbeau-Frugier C; Game X; Allal A; Kamar N
Ther Apher Dial; 2016 Oct; 20(5):507-516. PubMed ID: 27073167
[TBL] [Abstract][Full Text] [Related]
5. Factors Predicting Risk for Antibody-mediated Rejection and Graft Loss in Highly Human Leukocyte Antigen Sensitized Patients Transplanted After Desensitization.
Vo AA; Sinha A; Haas M; Choi J; Mirocha J; Kahwaji J; Peng A; Villicana R; Jordan SC
Transplantation; 2015 Jul; 99(7):1423-30. PubMed ID: 25606792
[TBL] [Abstract][Full Text] [Related]
6. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
[TBL] [Abstract][Full Text] [Related]
7. Desensitization in the Setting of HLA-Incompatible Kidney Transplant.
Malvezzi P; Jouve T; Noble J; Rostaing L
Exp Clin Transplant; 2018 Aug; 16(4):367-375. PubMed ID: 29863455
[TBL] [Abstract][Full Text] [Related]
8. Highly Sensitized Patients: Miami Transplant Institute Experience.
Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib in ABO-incompatible kidney transplant desensitization: a case report.
Wong NL; O'Connell P; Chapman JR; Nankivell B; Kable K; Webster AC; Wong G
Nephrology (Carlton); 2015 Mar; 20 Suppl 1():22-4. PubMed ID: 25807854
[TBL] [Abstract][Full Text] [Related]
10. Living-Donor Kidney Transplant With Preformed Donor-Specific Antibodies.
Itabashi Y; Aikawa A; Muramatsu M; Hyoudou Y; Shinoda K; Takahashi Y; Sakurabayashi K; Mizutani T; Oguchi H; Arai T; Kawamura T; Hamasaki Y; Sakai K; Shishido S
Exp Clin Transplant; 2019 Jan; 17(Suppl 1):43-49. PubMed ID: 30777522
[TBL] [Abstract][Full Text] [Related]
11. Outcome of recipients of human leukocyte antigen incompatible kidney transplants who underwent desensitization at King Fahad Specialist Hospital, Dammam, Saudi Arabia.
Idris MA; Hossain A; Muntasir MA; Marmi A; Aldajani AA; Aljamaan YM; Akhtar M; Housawi A
Saudi J Kidney Dis Transpl; 2017; 28(3):499-506. PubMed ID: 28540885
[TBL] [Abstract][Full Text] [Related]
12. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
Yuan XP; Wang CX; Gao W; Fu Q; He XS
Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
[TBL] [Abstract][Full Text] [Related]
14. Treatment of antibody-mediated rejection including immunoadsorption during first year after renal transplantation--Clinical results and regulation of endothelial progenitor cells.
Opgenoorth M; Wagner A; Passauer J; Hohenstein B; Hugo C
Atheroscler Suppl; 2015 May; 18():67-73. PubMed ID: 25936307
[TBL] [Abstract][Full Text] [Related]
15. Effects of Two Preemptive Post-transplant Desensitization Regimens Upon Renal Allograft Survival and DSA Elaboration.
Kimball PM; McDougan FA; King A
Clin Transpl; 2014; ():197-203. PubMed ID: 26281145
[TBL] [Abstract][Full Text] [Related]
16. Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption.
Becker LE; Siebert D; Süsal C; Opelz G; Leo A; Waldherr R; Macher-Goeppinger S; Schemmer P; Schaefer SM; Klein K; Beimler J; Zeier M; Schwenger V; Morath C
Transplantation; 2015 Nov; 99(11):2364-71. PubMed ID: 25989497
[TBL] [Abstract][Full Text] [Related]
17. The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends.
Sanoff SL; Balogun RA; Lobo PL
Semin Dial; 2012; 25(2):193-200. PubMed ID: 22321316
[TBL] [Abstract][Full Text] [Related]
18. High immunologic risk living donor kidney transplant using bortezomib in a novel induction regimen without acute antibody mediated rejection.
Dunn TB; Borja-Cacho D; Chinnakotla S; Finger E; Tamayo G; Verghese P; Kim Y; Manivel C; Kandaswamy R; Matas A; Pruett T; Noreen H; Krefting P; Maurer D
Clin Transpl; 2011; ():381-7. PubMed ID: 22755435
[TBL] [Abstract][Full Text] [Related]
19. Desensitization in kidney transplantation: review and future perspectives.
Abu Jawdeh BG; Cuffy MC; Alloway RR; Shields AR; Woodle ES
Clin Transplant; 2014 Apr; 28(4):494-507. PubMed ID: 24621089
[TBL] [Abstract][Full Text] [Related]
20. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody.
Moreno Gonzales MA; Gandhi MJ; Schinstock CA; Moore NA; Smith BH; Braaten NY; Stegall MD
Transplantation; 2017 Jun; 101(6):1222-1227. PubMed ID: 27379560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
